Samsung Biologics (Samba) held its 13th regular shareholders' meeting at Songdo Convensia in Incheon on the 15th.
Samba explained that it will accelerate its strategy to expand its three pillars (production capacity, business portfolio, and geographic base) and strengthen the value of '4E' such as customer satisfaction, operational efficiency, highest quality, and employee capabilities.
The construction of the Songdo 5 plant, which is under construction with the aim of completing in April next year, is underway without a hitch, and it added that it will secure competitiveness in the ADC field through an antibody-drug conjugate (ADC) dedicated production facility scheduled to be completed in December.
Seo Seung-hwan, an honorary professor at Yonsei University, was newly appointed as an outside director and audit committee member.
This year, the remuneration limit for directors was frozen at 15 billion won, and 9.35 billion won out of the 15 billion won limit for directors was actually executed last year.
"It is expected that the difficult business environment will continue this year, but we will not stop challenging global top tier companies," Samba President Jonlim said. "All executives and employees will work together as one team to show the best results."
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
